AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines
By: Saram Abbas , Naeem Soomro , Rishad Shafik and more
Potential Business Impact:
Helps doctors predict bladder cancer return better.
Bladder cancer claims one life every 3 minutes worldwide. Most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), yet up to 70% recur after treatment, triggering a relentless cycle of surgeries, monitoring, and risk of progression. Clinical tools like the EORTC risk tables are outdated and unreliable - especially for intermediate-risk cases. We propose an interpretable AI model using the Tsetlin Machine (TM), a symbolic learner that outputs transparent, human-readable logic. Tested on the PHOTO trial dataset (n=330), TM achieved an F1-score of 0.80, outperforming XGBoost (0.78), Logistic Regression (0.60), and EORTC (0.42). TM reveals the exact clauses behind each prediction, grounded in clinical features like tumour count, surgeon experience, and hospital stay - offering accuracy and full transparency. This makes TM a powerful, trustworthy decision-support tool ready for real-world adoption.
Similar Papers
Attention-enabled Explainable AI for Bladder Cancer Recurrence Prediction
Machine Learning (CS)
Predicts bladder cancer return to guide treatment.
Breast Cancer Recurrence Risk Prediction Based on Multiple Instance Learning
CV and Pattern Recognition
Helps doctors predict cancer return using pictures.
Differentiated Thyroid Cancer Recurrence Classification Using Machine Learning Models and Bayesian Neural Networks with Varying Priors: A SHAP-Based Interpretation of the Best Performing Model
Machine Learning (CS)
Predicts cancer return with better accuracy.